This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Gebru, E.
Right arrow Articles by Park, S.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gebru, E.
Right arrow Articles by Park, S.-C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2009, p. 3024-3029, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.01346-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Integration of Pharmacokinetic and Pharmacodynamic Indices of Orbifloxacin in Beagle Dogs after a Single Intravenous and Intramuscular Administration{triangledown}

Elias Gebru,1 Joong-Su Lee,1 Zhi-Qiang Chang,1 Mi-Hyun Hwang,1 Henrique Cheng,2 and Seung-Chun Park1*

College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, South Korea,1 School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 708032

Received 8 October 2008/ Returned for modification 17 January 2009/ Accepted 19 April 2009

The pharmacokinetics (PK) and pharmacodynamics (PD) of orbifloxacin were studied in beagle dogs after intravenous (i.v.) and intramuscular (i.m.) administration at a dose of 2.5 mg/kg body weight. An absolute bioavailability of 100.1% ± 4.76%, a terminal half-life of 4.23 ± 0.2 h and 3.95 ± 0.15 h after i.v. and i.m. administration, a steady-state volume of distribution of 1.61 ± 0.13 liters/kg, and clearance of 0.31 ± 0.03 liters/h/kg were observed. Orbifloxacin showed rapid, concentration-dependent killing against the Escherichia coli, Staphylococcus aureus, Staphylococcus intermedius, and Proteus mirabilis clinical isolates. Computations based on PK-PD analysis indicated that the recommended dose is unlikely to be clinically effective against some strains like S. intermedius. Therefore, a higher dose of orbifloxacin would be worthy of consideration for treatment of certain bacterial infections in dogs.

* Corresponding author. Mailing address: College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, South Korea. Phone: 82-53-950-5964. Fax: 82-53-950-5955. E-mail: parksch{at}knu.ac.kr

{triangledown} Published ahead of print on 27 April 2009.

Antimicrobial Agents and Chemotherapy, July 2009, p. 3024-3029, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.01346-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»